Global medical device company Apos Medical Assets, and market access consultancy Spirit Access, are partnering to help CCGs and NHS Trusts improve health outcomes with an innovative treatment for patients with chronic knee conditions.
There is a pressing need to make the NHS Pathway for chronic knee conditions more efficient. The number of total knee replacements in the UK has risen significantly over the last 15 years. In 2016/17 the UK National Joint Registry recorded 108,713 knee replacements, an increase of 3.8% over the previous year.
The AposTherapy treatment programme can postpone, and even prevent knee replacement surgeries. During the initial year of AposTherapy treatment, 87% of patients avoid surgery. As a result of the avoided surgeries, one mid-size CCG achieved an estimated savings of £3,330 per patient. In addition to saving costs by reducing the number of knee replacement surgeries, AposTherapy may save additional costs by reducing the amount of musculoskeletal, outpatient visits, radiology, injections and opioid use.
Cliff Bleustein, global president and CEO of Apos Medical Assets, said: “There is a growing need for a clinically proven non-surgical knee pain treatment which can benefit CCGs economically while benefiting patients clinically. We recognise the need for greater market access in the UK and are excited to be working with Spirit Access in order to make AposTherapy available to the population through more CCGs.”
